Eli Lilly (LLY) earnings Q1 2026
David Ricks, CEO of Eli Lilly & Co., at the Semaphore World Economic Summit during the International Monetary Fund (IMF) and World Bank Spring meetings on Friday, April 17, 2026 in Washington, DC, USA.
Aaron Schwartz | Bloomberg | Getty Images
Eli Lilly It will report first-quarter earnings before the bell rings on Thursday, in one of the healthcare industry’s most closely watched reports.
According to a survey of analysts conducted by LSEG, Wall Street’s expectations are as follows:
- Earnings per share: $6.66 adjusted expectation
- Revenues: 17.62 billion dollars is expected
Demand for the company’s blockbuster obesity drug Zepbound and its diabetes counterpart Mounjaro has helped Lilly, which has a majority market share in the emerging GLP-1 space, post several solid quarters.
According to StreetAccount estimates, analysts expect Zepbound to generate total sales of $4.04 billion, with $3.98 billion of that coming from the United States. Meanwhile, according to StreetAccount estimates, they expect Mounjaro to record worldwide sales of $7.26 billion, including US revenue of $3.87 billion.
Foundayo, the company’s newly approved GLP-1 anti-obesity pill, launched in the second quarter, so its sales won’t be included in Thursday’s report.
Still, the pill’s launch looks set to dominate the discussion during Lilly’s first-quarter earnings call. Executives will likely face questions about whether Foundayo can achieve the same level of momentum as the rival Wegovy pill. Novo NordiskEnjoying a three-month benefit in the USA
It’s too early to judge the performance of Lilly’s pill. But preliminary prescription data suggests initial distribution is “modest,” according to a note last week from Leerink Partners analyst David Risinger.
In February, Lilly said it expects to benefit from the launch of Foundayo, Medicare coverage of obesity drugs later this year and continued worldwide demand for Mounjaro and Zepbound. But the company also expects to face pricing pressure caused by the drug pricing agreement with President Donald Trump and lower cashback prices for Zepbound, among other factors.
Still, Lilly CEO Dave Ricks said: an interview In late April, it said it expected lower prices to accelerate prescription volumes in the United States. He also predicted that global GLP-1 use will rise from about 20 million patients at the end of last year to 30 million by the end of 2026.
